

PCT

WELTOORGANISATION FÜR GEISTIGES EIGENTUM
Internationales Büro



INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

(51) Internationale Patentklassifikation ⁷ : C12N 15/11, A61K 31/713		A1	(11) Internationale Veröffentlichungsnummer: WO 00/44895
			(43) Internationales Veröffentlichungsdatum: 3. August 2000 (03.08.00)
(21) Internationales Aktenzeichen: PCT/DE00/00244		(81) Bestimmungsstaaten: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) Internationales Anmeldedatum: 29. Januar 2000 (29.01.00)			
(30) Prioritätsdaten: 199 03 713.2 30. Januar 1999 (30.01.99) DE 199 56 568.6 24. November 1999 (24.11.99) DE			
(71)(72) Anmelder und Erfinder: KREUTZER, Roland [DE/DE]; Glotzdorf 26, D-95466 Weidenberg (DE). LIMMER, Stephan [DE/DE]; Leibnizstrasse 14, D-95447 Bayreuth (DE).		Veröffentlicht <i>Mit internationalem Recherchenbericht. Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist; Veröffentlichung wird wiederholt falls Änderungen eintreffen.</i>	
(74) Anwalt: GASSNER, Wolfgang; Nägelebachstrasse 49 A, D-91052 Erlangen (DE).			
(54) Titel: METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A DEFINED GENE			
(54) Bezeichnung: VERFAHREN UND MEDIKAMENT ZUR HEMMUNG DER EXPRESSION EINES VORGEgebenEN GENS			
(57) Abstract <p>The invention relates to a medicament containing at least one double-stranded oligoribonucleotide (dsRNA) designed to inhibit the expression of a target gene. According to the invention, one strand of the dsRNA is at least in part complementary to the target gene.</p>			
(57) Zusammenfassung <p>Die Erfindung betrifft ein Medikament mit mindestens einem Oligoribonukleotid mit doppelsträniger Struktur (dsRNA) zur Hemmung der Expression eines Zielgens, wobei ein Strang der dsRNA zumindest abschnittsweise komplementär zum Zielgen ist.</p>			

(57) Abstract

The invention relates to a medicament containing at least one double-stranded oligoribonucleotide (dsRNA) designed to inhibit the expression of a target gene. According to the invention, one strand of the dsRNA is at least in part complementary to the target gene.

WO 00/44895

PCT/DE00/00244

Method and medicament for inhibiting the expression of
a given gene

The invention relates to methods in accordance with the
5 preambles of claims 1 and 2. It furthermore relates to
a medicament and to a use of double-stranded
oligoribonucleotides and to a vector encoding them.

Such a method is known from WO 99/32619, which was
10 unpublished at the priority date of the present
invention. The known process aims at inhibiting the
expression of genes in cells of invertebrates. To this
end, the double-stranded oligoribonucleotide must
exhibit a sequence which is identical with the target
15 gene and which has a length of at least 50 bases. To ²⁵⁺
achieve efficient inhibition, the identical sequence
must be 300 to 11,000 base pairs in length. Such an
oligoribonucleotide is complicated to prepare.

20 DE 196 31 919 C2 describes an antisense RNA with
specific secondary structures, the antisense RNA being
present in the form of a vector encoding it. The
antisense RNA takes the form of an RNA molecule which
is complementary to regions of the mRNA. Inhibition of
25 the gene expression is caused by binding to these
regions. This inhibition can be employed in particular
for the diagnosis and/or therapy of diseases, for
example tumor diseases or viral infections. - The
disadvantage is that the antisense RNA must be
30 introduced into the cell in an amount which is at least
as high as the amount of the mRNA. The known antisense
methods are not particularly effective.

US 5,712,257 discloses a medicament comprising
35 mismatched double-stranded RNA (dsRNA) and bioactive
mismatched fragments of dsRNA in the form of a ternary
complex together with a surfactant. The dsRNA used for
this purpose consists of synthetic nucleic acid single
strands without defined base sequence. The single

- 2 -

strands undergo irregular base pairing, also known as "non-Watson-Crick" base pairing, giving rise to mismatched double strands. The known dsRNA is used to inhibit the amplification of retroviruses such as HIV.

5 Amplification of the virus can be inhibited when non-sequence-specific dsRNA is introduced into the cells. This leads to the induction of interferon, which is intended to inhibit viral amplification. The inhibitory effect, or the activity, of this method is poor.

10 It is known from Fire, A. et al., NATURE, Vol. 391, pp. 806 that dsRNA whose one strand is complementary in segments to a nematode gene to be inhibited inhibits the expression of this gene highly efficiently. It is
15 believed that the particular activity of the dsRNA used in nematode cells is not due to the antisense principle but possibly on catalytic properties of the dsRNA, or enzymes induced by it. - Nothing is mentioned in this paper on the activity of specific dsRNA with regard to
20 inhibiting the gene expression, in particular in mammalian and human cells.

The object of the present invention is to do away with the disadvantages of the prior art. In particular, it
25 is intended to provide as effective as possible a method, medicament or use for the preparation of a medicament, which method, medicament or use is capable of causing particularly effective inhibition of the expression of a given target gene.

30 This object is achieved by the features of claims 1, 2, 37, 38 and 74 and 75. Advantageous embodiments can be seen from claims 3 to 36, 39 to 73 and 76 to 112.

35 In accordance with the method-oriented inventions, it is provided in each case that the region I, which is complementary to the target gene, exhibits not more than 49 successive nucleotide pairs.

- 3 -

Provided in accordance with the invention are an oligoribonucleotide or a vector encoding therefor. At least segments of the oligoribonucleotide exhibit a defined nucleotide sequence. The defined segment may be 5 limited to the complementary region I. However, it is also possible that all of the double-stranded oligoribonucleotide exhibits a defined nucleotide sequence.

10 Surprisingly, it has emerged that an effective inhibition of the expression of the target gene can be achieved even when the complementary region I is not more than 49 base pairs in length. The procedure of providing such oligoribonucleotides is less 15 complicated.

In particular, dsRNA with a length of over 50 nucleotide pairs induces certain cellular mechanisms, for example the dsRNA-dependent protein 20 kinase or the 2-5A system, in mammalian and human cells. This leads to the disappearance of the interference effect mediated by the dsRNA which exhibits a defined sequence. As a consequence, protein biosynthesis in the cell is blocked. The present 25 invention overcomes this disadvantage in particular.

Furthermore, the uptake of dsRNA with short chain lengths into the cell or into the nucleus is facilitated markedly over longer-chain dsRNAs.

30 It has proved advantageous for the dsRNA or the vector to be present packaged into micellar structures, preferably in liposomes. The dsRNA or the vector can likewise be enclosed in viral natural capsids or in 35 chemically or enzymatically produced artificial capsids or structures derived therefrom. - The abovementioned features make it possible to introduce the dsRNA or the vector into given target cells.

- 4 -

In a further aspect, the dsRNA has 10 to 1 000, preferably 15 to 49, base pairs. Thus, the dsRNA can be longer than the region I, which is complementary to the target gene. The complementary region I can be located 5 at the terminus or inserted into the dsRNA. Such dsRNA or a vector provided for coding the same can be produced synthetically or enzymatically by customary methods.

10 The gene to be inhibited is expediently expressed in eukaryotic cells. The target gene can be selected from the following group: oncogene, cytokin gene, Id protein gene, developmental gene, prion gene. It can also be expressed in pathogenic organisms, preferably in 15 plasmobia. It can be part of a virus or viroid which is preferably pathogenic to humans. - The method proposed makes it possible to produce compositions for the therapy of genetically determined diseases, for example cancer, viral diseases or Alzheimer's disease.

20 The virus or viroid can also be a virus or viroid which is pathogenic to animals or plant-pathogenic. In this case, the method according to the invention also permits the provision of compositions for treating 25 animal or plant diseases.

In a further aspect, segments of the dsRNA are designed as double-stranded. A region II which is complementary within the double-stranded structure is formed by two 30 separate RNA single strands or by autocomplementary regions of a topologically closed RNA single strand ~~which is preferably in circular form.~~

35 The ends of the dsRNA can be modified to counteract degradation in the cell or dissociation into the single strands. Dissociation takes place in particular when low concentrations or short chain lengths are used. To inhibit dissociation in a particularly effective fashion, the cohesion of the complementary region II,

- 5 -

which is caused by the nucleotide pairs, can be increased by at least one, preferably two, further chemical linkage(s). - A dsRNA according to the invention whose dissociation is reduced exhibits 5 greater stability to enzymatic and chemical degradation in the cell or in the organism.

The complementary region II can be formed by 10 autocomplementary regions of an RNA hairpin loop, in particular when using a vector according to the invention. To afford protection from degradation, it is expedient for the nucleotides to be chemically modified in the loop region between the double-stranded structure.

15 The chemical linkage is expediently formed by a covalent or ionic bond, a hydrogen bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal-ion coordination. In an 20 especially advantageous aspect, it can be formed at at least one, preferably both, end(s) of the complementary region II.

25 It has furthermore proved to be advantageous for the chemical linkage to be formed by one or more linkage groups, the linkage groups preferably being poly(oxyphosphinicoxy-1,3-propanediol) and/or ~~poly~~ ~~ethylene glycol chains~~. The chemical linkage can also 30 be formed by purine analogs used in place of purines in the complementary regions II. It is also advantageous for the chemical linkage to be formed by azabenzene units introduced into the complementary regions II. Moreover, it can be formed by branched nucleotide analogs used in place of nucleotides in the 35 complementary regions II.

It has proved expedient to use at least one of the following groups for generating the chemical linkage: methylene blue; bifunctional groups, preferably

- 6 -

bis(2-chloroethyl)amine; N-acetyl-N'-(p-glyoxyl-benzoyl)cystamine; 4-thiouracil; psoralene. The chemical linkage can furthermore be formed by thiophosphoryl groups provided at the ends of the 5 double-stranded region. The chemical linkage at the ends of the double-stranded region is preferably formed by triple-helix bonds.

The chemical linkage can expediently be induced by 10 ultraviolet light.

~~The nucleotides of the dsRNA can be modified. This counteracts the activation, in the cell, of a double-stranded-RNA-dependent protein kinase, PKR.~~

15 Advantageously, at least one 2'-hydroxyl group of the nucleotides of the dsRNA in the complementary region II is replaced by a chemical group, preferably a 2'-amino or a 2'-methyl group. At least one nucleotide in at least one strand of the complementary region II can 20 also be a locked nucleotide with a sugar ring which is chemically modified, preferably by a 2'-O, 4'-C methylene bridge. Advantageously, several nucleotides are locked nucleotides.

25 A further especially advantageous embodiment provides that the dsRNA or the vector is bound to, associated with or surrounded by, at least one viral coat protein which originates from a virus, is derived therefrom or has been prepared synthetically. The coat protein can 30 be derived from polyomavirus. The coat protein can contain the polyomavirus virus protein 1 (VP1) and/or virus protein 2 (VP2). The use of such coat proteins is known from, for example, DE 196 18 797 A1, whose disclosure is herewith incorporated. - The 35 abovementioned features considerably facilitate the introduction of the dsRNA or of the vector into the cell.

- 7 -

When a capsid or capsid-type structure is formed from the coat protein, one side preferably faces the interior of the capsid or capsid-type structure. The construct formed is particularly stable.

5

The dsRNA can be complementary to the primary or processed RNA transcript of the target gene. - The cell can be a vertebrate cell or a human cell.

- 10 10 At least two dsRNAs which differ from each other or at least one vector encoding them can be introduced into the cell, where at least segments of one strand of each dsRNA are complementary to in each case one of at least two different target genes. This makes it possible
- 15 15 simultaneously to inhibit the expression of at least two different target genes. In order to suppress, in the cell, the expression of a double-stranded-RNA-dependent protein kinase, PKR, one of the target genes is advantageously the PKR gene. This allows effective
- 20 20 suppression of the PKR activity in the cell.

The invention furthermore provides a medicament with at least one oligoribonucleotide with double-stranded structure (dsRNA) for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to the target gene. - Surprisingly, it has emerged that such a dsRNA is suitable as medicament for inhibiting the expression of a given gene in mammalian cells. In comparison with the use of single-stranded oligoribonucleotides, the inhibition is already caused at concentrations which are lower by at least one order of magnitude. The medicament according to the invention is highly effective. Lesser side effects can be expected.

The invention furthermore provides a medicament with at least one vector for coding at least one oligoribonucleotide with double-stranded structure

- 8 -

(dsRNA) for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to the target gene. - The medicament proposed exhibits the 5 abovementioned advantages. By using a vector, in particular production costs can be reduced.

In a particularly advantageous embodiment, the complementary region I has not more than 49 successive 10 nucleotide pairs. - Surprisingly, it has emerged that an effective inhibition of the expression of the target gene can be achieved even when the complementary region I is not more than 49 base pairs in length. The procedure of providing such oligoribonucleotides is 15 less complicated.

The invention furthermore provides a use of an oligoribonucleotide with double-stranded structure (dsRNA) for preparing a medicament for inhibiting the 20 expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to the target gene. - Surprisingly, such a dsRNA is suitable for preparing a medicament for inhibiting the expression of a given gene. Compared 25 with the use of single-stranded oligoribonucleotides, the inhibition is already caused at concentrations which are lower by one order of magnitude when using dsRNA. The use according to the invention thus makes possible the preparation of particularly effective 30 medicaments.

The invention furthermore provides the use of a vector for coding at least one oligoribonucleotide with double-stranded structure (dsRNA) for preparing a 35 medicament for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to this target gene. - The use of a vector makes possible a particularly effective gene therapy.

With regard to advantageous embodiments of the medicament and of the use, reference is made to the description of the above features.

5

Use examples of the invention are illustrated in greater detail hereinbelow with reference to the figures, in which:

10 Fig. 1 shows the schematic representation of a plasmid for the *in vitro* transcription with T7- and SP6-polymerase,

15 Fig. 2 shows RNA following electrophoresis on an 8% polyacrylamide gel and staining with ethidium bromide,

20 Fig. 3 shows a representation of radioactive RNA transcripts following electrophoresis on an 8% polyacrylamide gel with 7 M urea by means of an instant imager, and

Figs. 4a - e show Texas Red and YFP fluorescence in murine fibroblasts.

25

Use example 1:

30 The inhibition of transcription was detected by means of sequence homologous dsRNA in an *in vitro* transcription system with a nuclear extract from human HeLa cells. The DNA template for this experiment was plasmid pCMV1200 which had been linearized by means of BamHI.

Generation of the template plasmids:

35 The plasmid shown in fig. 1 was constructed for use in the enzymatic synthesis of the dsRNA. To this end, a polymerase chain reaction (PCR) with the "positive control DNA" of the HelaScribe[®] Nuclear Extract *in vitro* transcription kit by Promega, Madison, USA, as

- 10 -

DNA template was first carried out. One of the primers used contained the sequence of an EcoRI cleavage site and of the T7 RNA polymerase promoter as shown in sequence listing No. 1. The other primer contained the 5 sequence of a BamHI cleavage site and of the SP6 RNA polymerase promoter as shown in sequence listing No. 2. In addition, the two primers had, at the 3' ends, regions which were identical with or complementary to the DNA template. The PCR was carried out by means of 10 the "Tag PCR Core Kits" by Qiagen, Hilden, Germany, following the manufacturer's instructions. 1.5 mM MgCl₂, in each case 200 μM dNTP, in each case 0.5 μM primer, 2.5 U Tag DNA polymerase and approximately 100 ng of "positive control DNA" were employed as 15 template in PCR buffer in a volume of 100 μl. After initial denaturation of the template DNA by heating for 5 minutes at 94°C, amplification was carried out in 30 cycles of denaturation for in each case 60 seconds at 94°C, annealing for 60 seconds at 5°C below the 20 calculated melting point of the primers and polymerization for 1.5-2 minutes at 72°C. After a final polymerization of 5 minutes at 72°C, 5 μl of the reaction were analyzed by agarose-gel electrophoresis. The length of the DNA fragment amplified thus was 25 400 base pairs, 340 base pairs corresponding to the "positive control DNA". The PCR product was purified, hydrolyzed with EcoRI and BamHI and, after repurification, employed in the ligation together with a pUC18 vector which had also been hydrolyzed by EcoRI 30 and BamHI. *E. coli* XL1-blue was then transformed. The plasmid obtained (pCMV5) carries a DNA fragment whose 5' end is flanked by the T7 promoter and whose 3' end is flanked by the SP6 promoter. By linearizing the plasmid with BamHI, it can be employed *in vitro* with 35 the T7-RNA polymerase for the run-off transcription of a single-stranded RNA which is 340 nucleotides in length and shown in sequence listing No. 3. If the plasmid is linearized with EcoRI, it can be employed for the run-off transcription with SP6 RNA polymerase.

- 11 -

giving rise to the complementary strand. In accordance with the method outlined hereinabove, an RNA 23 nucleotides in length was also synthesized. To this end, a DNA shown in sequence listing No. 4 was ligated 5 with the pUC18 vector via the EcoRI and BamHI cleavage sites.

Plasmid pCMV1200 was constructed as DNA template for the *in-vitro* transcription with HeLa nuclear extract. 10 To this end, a 1 191 bp EcoRI/BamHI fragment of the positive control DNA contained in the HeLaScribe® Nuclear Extract *in vitro* transcription kit was amplified by means of PCR. The amplified fragment encompasses the 828 bp "immediate early" CMV promoter 15 and a 363 bp transcribable DNA fragment. The PCR product was ligated to the vector pGEM-T via "T-overhang" ligation. A BamHI cleavage site is located at the 5' end of the fragment. The plasmid was linearized by hydrolysis with BamHI and used as 20 template in the run-off transcription.

In-vitro transcription of the complementary single strands:

pCMV5 plasmid DNA was linearized with EcoRI or BamHI. 25 It was used as DNA template for an *in-vitro* transcription of the complementary RNA single strands with SP6 and T7 RNA polymerase, respectively. The "Riboprobe *in vitro* Transcription" system by Promega, Madison, USA, was employed for this purpose. Following 30 the manufacturer's instructions, 2 µg of linearized plasmid DNA were incubated in 100 µl of transcription buffer and 40 U T7 or SP6 RNA polymerase for 5-6 hours at 37°C. The DNA template was subsequently degraded by addition of 2.5 µl of RNase-free DNase RQ1 and 35 incubation for 30 minutes at 37°C. The transcription reaction was made up to 300 µl with H₂O and purified by phenol extraction. The RNA was precipitated by addition of 150 µl of 7 M ammonium acatate [sic] and 1 125 µl of

- 12 -

ethanol and stored at -65°C until used for the hybridization.

Generation of the RNA double strands:

- 5 For the hybridization, 500 μ l of the single-stranded RNA which had been stored in ethanol and precipitated were spun down. The resulting pellet was dried and taken up in 30 μ l of PIPES buffer, pH 6.4 in the presence of 80% formamide, 400 mM NaCl and 1 mM EDTA.
- 10 In each case 15 μ l of the complementary single strands were combined and heated for 10 minutes at 85°C. The reactions were subsequently incubated overnight at 50°C and cooled to room temperature.
- 15 Only approximately equimolar amounts of the two single strands were employed in the hybridization. This is why the dsRNA preparations contained single-stranded RNA (ssRNA) as contaminant. In order to remove these ssRNA contaminants, the reactions were treated, after
- 20 hybridization, with the single-strand-specific ribonucleases bovine pancreatic RNase A and *Aspergillus oryzae* RNase T1. RNase A is an endoribonuclease which is specific for pyrimidines. RNase T1 is an endoribonuclease which preferentially cleaves at the 3' side of guanosines. dsRNA is no substrate for these ribonucleases. For the RNase treatment, the reactions in 300 μ l of Tris, pH 7.4, 300 mM NaCl and 5 mM EDTA were treated with 1.2 μ l of RNaseA at a concentration of 10 mg/ml and 2 μ l of RNaseT1 at a concentration of
- 25 300 μ g/ml. The reactions were incubated for 1.5 hours at 30°C. Thereupon, the RNases were denatured by addition of 5 μ l of proteinase K at a concentration of 20 mg/ml and 10 μ l of 20% SDS and incubation for 30 minutes at 37°C. The dsRNA was purified by phenol
- 30 extraction and precipitated with ethanol. To verify the completeness of the RNase digestion, two control reactions were treated with ssRNA analogously to the hybridization reactions.

- 13 -

The dried pellet was taken up in 15 μ l of TE buffer, pH 6.5, and subjected to native polyacrylamide gel electrophoresis on an 8% gel. The acrylamide gel was subsequently stained in an ethidium bromide solution 5 and washed in a water bath. Fig. 2 shows the RNA which had been visualized in a UV transilluminator. The sense RNA which had been applied to lane 1 and the antisense RNA which had been applied to lane 2 showed a different migration behavior under the chosen conditions than the 10 dsRNA of the hybridization reaction which had been applied to lane 3. The RNase-treated sense RNA and antisense RNA which had been applied to lanes 4 and 5, respectively, produced no visible band. This shows that the single-stranded RNAs had been degraded completely. 15 The RNase-treated dsRNA of the hybridization reaction which had been applied to lane 6 is resistant to RNase treatment. The band which migrates faster in the native gel in comparison with the dsRNA applied to lane 3 results from dsRNA which is free from ssRNA. In 20 addition to the dominant main band, weaker bands which migrate faster are observed after the RNase treatment.

In-vitro transcription test with human nuclear extract:

Using the HeLaScribe[®] Nuclear Extract in vitro 25 transcription kit by Promega, Madison, USA, the transcription efficiency of the abovementioned DNA fragment which is present in plasmid pCMV1200 and homologous to the "positive control DNA" was determined in the presence of the dsRNA (dsRNA-CMV5) with sequence 30 homology. Also, the effect of the dsRNA without sequence homology, which corresponds to the yellow fluorescent protein (YFP) gene (dsRNA-YRP), was studied. This dsRNA had been generated analogously to the dsRNA with sequence homology. The sequence of a 35 strand of this dsRNA can be found in sequence listing No. 5. Plasmid pCMV1200 was used as template for the run-off transcription. It carries the "immediate early" cytomegalovirus promoter which is recognized by the eukaryotic RNA polymerase II, and a transcribable DNA

- 14 -

fragment. Transcription was carried out by means of the HeLa nuclear extract, which contains all the proteins which are necessary for transcription. By addition of [$\cdot\cdot\cdot^{32}P$]rGTP to the transcription reaction, radiolabeled transcript was obtained. The [$\cdot\cdot\cdot^{32}P$]rGTP used had a specific activity of 400 Ci/mmol, 10 mCi/ml. 3 mM MgCl₂, in each case 400 μ M rATP, rCTP, rUTP, 16 μ M rGTP, 0.4 μ M [$\cdot\cdot\cdot^{32}P$]rGTP and depending on the experiment 1 fmol of linearized plasmid DNA and various amounts of dsRNA in transcription buffer were employed per reaction. Each batch was made up to a volume of 8.5 μ l with H₂O. The reactions were mixed carefully. To start the transcription, 4 U HeLa nuclear extract in a volume of 4 μ l were added and incubated for 60 minutes at 30°C. The reaction was stopped by addition of 87.5 μ l of quench mix which had been warmed to 30°C. To remove the proteins, the reactions were treated with 100 μ l of phenol/chloroform/isoamyl alcohol (25:24:1 v/v/v) saturated with TE buffer, pH 5.0, and the reactions were mixed vigorously for 1 minute. For phase separation, the reactions were spun for approximately 1 minute at 12 000 rpm and the top phase was transferred into a fresh reaction vessel. Each reaction was treated with 250 μ l of ethanol. The reactions were mixed thoroughly and incubated for at least 15 minutes on dry ice/methanol. To precipitate the RNA, the reactions were spun for 20 minutes at 12 000 rpm and 40°C. The supernatant was discarded. The pellet was dried in vacuo for 15 minutes and resuspended in 10 μ l of H₂O. Each reaction was treated with 10 μ l of denaturing loading buffer. The free GTP was separated from the transcript formed by means of denaturing polyacrylamide gel electrophoresis on an 8% gel with 7 M urea. The RNA transcripts formed upon transcription with HeLa nuclear extract, in denaturing loading buffer, were heated for 10 minutes at 90°C and 10 μ l aliquots were applied immediately to the freshly washed pockets. The electrophoresis was run at 40 mA. The amount of the radioactive ssRNA formed upon

- 15 -

transcription was analyzed after electrophoresis with the aid of an *Instant Imager*.

Fig. 3 shows the radioactive RNA from a representative 5 test, shown by means of the *Instant Imager*. Samples obtained from the following transcription reactions were applied:

Lane 1: without template DNA, without dsRNA;
10 Lane 1: 50 ng of template DNA, without dsRNA;
Lane 3: 50 ng of template DNA, 0.5 μ g of dsRNA YFP;
Lane 4: 50 ng of template DNA, 1.5 μ g of dsRNA YFP;
Lane 5: 50 ng of template DNA, 3 μ g of dsRNA YFP;
Lane 6: 50 ng of template DNA, 5 μ g of dsRNA YFP;
15 Lane 7: without template DNA, 1.5 dsRNA YFP;
Lane 8: 50 ng of template DNA, without dsRNA;
Lane 9: 50 ng of template DNA, 0.5 μ g of dsRNA CMV5;
Lane 10: 50 ng of template DNA, 1.5 μ g of dsRNA CMV5;
Lane 11: 50 ng of template DNA, 3 μ g of dsRNA CMV5;
20 Lane 12: 50 ng of template DNA, 5 μ g of dsRNA CMV5;

It emerged that the amount of transcript was reduced markedly in the presence of dsRNA with sequence homology in comparison with the control reaction 25 without dsRNA and with the reactions with dsRNA YFP without sequence homology. The positive control in lane 2 shows that radioactive transcript was formed upon the *in-vitro* transcription with HeLa nuclear extract. The reaction is used for comparison with the transcription 30 reactions which had been incubated in the presence of dsRNA. Lanes 3 to 6 show that the addition of non-sequentially-specific dsRNA YFP had no effect on the amount of transcript formed. Lanes 9 to 12 show that the addition of an amount of between 1.5 and 3 μ g of 35 sequentially-specific dsRNA CMV5 leads to a reduction in the amount of transcript formed. In order to exclude that the effects observed are based not on the dsRNA but on any contamination which might have been carried along accidentally during the preparation of the dsRNA,

- 16 -

a further control was carried out. Single-stranded RNA was transcribed as described above and subsequently subjected to the RNase treatment. It was demonstrated by means of native polyacrylamide gel electrophoresis
5 that the ssRNA had been degraded completely. This reaction was subjected to phenol extraction and ethanol precipitation and subsequently taken up in PE buffer, as were the hybridization reactions. This gave a sample which contained no RNA but had been treated with the
10 same enzymes and buffers as the dsRNA. Lane 8 shows that the addition of this sample had no effect on transcription. The reduction of the transcript upon addition of sequence-specific dsRNA can therefore be ascribed unequivocally to the dsRNA itself. The
15 reduction of the amount of transcript of a gene in the presence of dsRNA in a human transcription system indicates an inhibition of the expression of the gene in question. This effect can be attributed to a novel mechanism caused by the dsRNA.

20

Use example 2:

The test system used for these in-vivo experiments was the murine fibroblast cell line NIH3T3, ATCC CRL-1658. The YFP gene was introduced into the nuclei with the
25 aid of microinjection. Expression of YFP was studied under the effect of simultaneously cotransfected dsRNA with sequence homology. This dsRNA YFP shows homology with the 5'-region of the YFP gene over a length of 315 bp. The nucleotide sequence of a strand of the
30 dsRNA YRP is shown in sequence listing No. 5. Evaluation under the fluorescence microscope was carried out 3 hours after injection with reference to the greenish-yellow fluorescence of the YFP formed.

35 Construction of the template plasmid, and preparation of the dsRNA:

A plasmid was constructed following the same principle as described in use example 1 to act as template for the production of the YFP dsRNA by means of T7 and SP6

- 17 -

in-vitro transcription. Using the primer *Eco_T7_YFP* as shown in sequence listing No. 6 and *Bam_SP6_YFP* as shown in sequence listing No. 7, the desired gene fragment was amplified by PCR and used analogously to 5 the above description for preparing the dsRNA. The dsRNA YFP obtained is identical to the dsRNA used in use example 1 as non-sequence-specific control.

A dsRNA linked chemically at the 3' end of the RNA as 10 shown in sequence listing No. 8 to the 5' end of the complementary RNA via a C18 linker group was prepared (L-dsRNA). To this end, synthons modified by disulfide bridges were used. The 3'-terminal synthon is bound to the solid support via the 3' carbon with an aliphatic 15 linker group via a disulfide bridge. In the 5'-terminal synthon of the complementary oligoribonucleotide which is complementary to the 3'-terminal synthon of the one oligoribonucleotide, the 5'-trityl protecting group is bound via a further aliphatic linker and a disulfide 20 bridge. Following synthesis of the two single strands, removal of the protecting groups and hybridization of the complementary oligoribonucleotides, the thiol groups which form are brought into spatial vicinity. The single strands are linked to each other by 25 oxidation via their aliphatic linkers and a disulfide bridge. This is followed by purification with the aid of HPLC.

Preparation of the cell cultures:

30 The cells were incubated in DMEM supplemented with 4.5 g/l glucose, 10% fetal bovine serum in culture dishes at 37°C under a 7.5% CO₂ atmosphere and passaged before reaching confluence. The cells were detached with trypsin/EDTA. To prepare for microinjection, the 35 cells were transferred into Petri dishes and incubated further until microcolonies formed.

Microinjection:

For the microinjection, the culture dishes were removed from the incubator for approximately 10 minutes. Approximately 50 nuclei were injected singly per reaction within a marked area using the AIS microinjection system from Carl Zeiss, Göttingen, Germany. The cells were subsequently incubated for three more hours. For the microinjection, borosilicate glass capillaries from Hilgenberg GmbH, Malsfeld, Germany, with a diameter of less than 0.5 μm at the tip were prepared. The microinjection was carried out using a micromanipulator from Narishige Scientific Instrument Lab., Tokyo, Japan. The injection time was 0.8 seconds and the pressure was approximately 100 hPa. The transfection was carried out using the plasmid pCDNA YFP, which contains an approximately 800 bp BamHI/EcoRI fragment with the YFP gene in vector pcDNA3. The samples injected into the nuclei contained 0.01 $\mu\text{g}/\mu\text{l}$ of pCDNA-YFP and Texas Red coupled to dextran-70000 in 14 mM NaCl, 3 mM KCl, 10 mM KPO₄ [sic], pH 7.5. Approximately 100 μl of RNA with a concentration of 1 μM or, in the case of the L-dsRNA, 375 μM were additionally added.

The cells were studied under a fluorescence microscope with excitation with the light of the excitation wavelength of Texas Red, 568 nm, or of YFP, 488 nm. Individual cells were documented by means of a digital cameras. Figures 4a-e show the result for NIH3T3 cells. In the cells shown in Fig. 4a, sense-YFP-ssRNA has been injected, in Fig. 4b antisense-YFP-ssRNA, in Fig. 4c dsRNA-YFP, in Fig. 4d no RNA and in Fig. 4e L-dsRNA.

The field on the left shows in each case the fluorescence of cells with excitation at 568 nm. The fluorescence of the same cells at an excitation of 488 nm is seen on the right. The Texas Red fluorescence of all the cells shown demonstrates that the injection solution had been applied successfully into the nuclei

- 19 -

and that cells with successful hits were still alive after three hours. Dead cells no longer showed Texas Red fluorescence.

- 5 The right fields of each of figures 4a and 4b show that YFP expression was not visibly inhibited when the single-stranded RNA was injected into the nuclei. The right field of Fig. 4c shows cells whose YFP fluorescence was no longer detectable after the
- 10 injection of dsRNA-YFP. Fig. 4d shows cells into which no RNA had been injected, as control. The cell shown in fig. 4e shows YFP fluorescence which can no longer be detected owing to the injection of the L-dsRNA which shows regions with sequence homology to the YFP gene.
- 15 This result demonstrates that even shorter dsRNAs can be used for specifically inhibiting gene expression in mammals when the double strands are stabilized by chemically linking the single strands.

194

Literature:

Asanuma, H., Ito, T., Yoshida, T., Liang, X. & Komiyama, M. (1999). Photoregulation der Bildung und Dissoziation eines DNA-Duplexes durch *cis-trans*-Isomerisierung einer Azobenzoleinheit. *Angew. Chem.* **111**, 2547-2549.

Azhayeva, E., Azhayev, A., Auriola, S., Tengvall, U., Urtti, A. & Lönnberg, H. (1997). Inhibitory properties of double helix forming circular oligonucleotides. *Nucl. Acids Res.* **25**, 4954-4961.

Castelli, J., Wood, K.A. & Youle, R.J. (1998). The 2-5A system in viral infection and apoptosis. *Biomed. Pharmacother.* **52**, 386-390.

Dolinnaya, N.G., Blumenfeld, M., Merenkova, I., Oretskaya, T.S., Krynetskaya, N.F., Ivanovskaya, M.G., Vasseur, M. & Shabarova, Z.A. (1993). Oligonucleotide circularization by template-directed chemical ligation. *Nucl. Acids Res.* **21**, 5403-5407.

Expert-Bezancon, A., Milet, M. & Carbon, P. (1983). Precise localization of several covalent RNA-RNA cross-link in *Escherichia coli* 16S RNA. *Eur. J. Biochem.* **136**, 267-274.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. & Mello, C.C. (1998). Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806-811.

19b

Gao, H., Yang, M., Patel, R. & Cook, A.F. (1995). Circularization of oligonucleotides by disulfide bridge formation. *Nucl. Acids Res.* 23, 2025-2029.

5 Gryaznov, S.M. & Letsinger, R.L. (1993). Template controlled coupling and recombination of oligonucleotide blocks containing thiophosphoryl groups. *Nucl. Acids Res.* 21, 1403-1408.

10 Kaufman, R.J. (1999). Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: A new role for an old actor. *Proc. Natl. Acad. Sci. USA* 96, 11693-11695.

15 Lipson, S.E. & Hearst, J.E. (1988). Psoralen cross-linking of ribosomal RNA. In *Methods in Enzymology* Anonymous pp. 330-341.

20 Liu, Z.R., Sargueil, B. & Smith, C.W. (1998). Detection of a novel ATP-dependent cross-linked protein at the 5' splice site-U1 small nuclear RNA duplex by methylene blue-mediated photo-cross-linking. *Mol. Cell. Biol.* 18, 6910-6920.

25 Micura, R. (1999). Cyclic oligoribonucleotides (RNA) by solid-phase synthesis. *Chem. Eur. J.* 5, 2077-2082.

30 Skripkin, E., Isel, C., Marquet, R., Ehresmann, B. & Ehresmann, C. (1996). Psoralen crosslinking between human immunodeficiency virus type 1 RNA and primer tRNA₃^{Lys}. *Nucl. Acids Res.* 24, 509-514.

19c

Wang, S. & Kool, E.T. (1994). Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs. *Nucl. Acids Res.* 22, 2326-2333.

5 Wang, Z. & Rana, T.M. (1996). RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking. *Biochem.* 35, 6491-6499.

Watkins, K.P. & Agabian, N. (1991). In vivo UV cross-linking
10 of U snRNAs that participate in trypanosome trans-
splicing. *Genes & Development* 5, 1859-1869.

Wengel, J. (1999). Synthesis of 3'-C- and 4'-C-branched oligo-
deoxynucleotides and the development of locked nucleic
15 acid (LNA). *Acc. Chem. Res.* 32, 301-310.

Zwieb, C., Ross, A., Rinke, J., Meinke, M. & Brimacombe, R.
(1978). Evidence for RNA-RNA cross-link formation in
Escherichia coli ribosomes. *Nucl. Acids Res.* 5, 2705-
20 2720.

WO 00/44895

PCT/DE00/00244

1

Sequence Listing

<110> Kreutzer Dr., Roland
Limmer Dr., Stephan

<120> Method and medicament for inhibiting the
expression of a given gene

<130> 400968

<140>

<141>

<150> 199 03 713.2

<151> 1999-01-30

<150> 199 56 568.6

<151> 1999-11-24

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:
EcoRI cleavage site, T7 RNA Polymerase
promoter

<400> 1

ggaattctaa ttcgtactca tataggggaa tcagatctct agaag

45

<210> 2

WO 00/44895

PCT/DE00/00244

2

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:
BamHI cleavage site, SP6 RNA Polymerase
promoter

<400> 2

gggatccatt taggtgacac tatagaatac ccatgatgc gtagtcgata

50

<210> 3

<211> 340

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:
RNA which corresponds to a sequence from the
positive control DNA of the HeLa Nuclear
Extract in vitro transcription kit from
Promega

<400> 3

ucagauccu agaaggcunua augggguaugu uuaucacagu uaaauugcua acgcagucag 60
gcaccggugua ugaaauccua caauggcgcc auggcuaucc ugggcacccgu caccggau 120
gguguaggca uaggcuguggu uaugecgguu cugccgggac ucuugcgga uaucguccau 180
ucgcacageca ucgcacaguca cuauggcgug cugcuaagcgc uauauggcguu gaugcaauuu 240
cuauugcgac ccguuucucgg agcacugucc gacgcguuug gcccggccc aguccugcuc 300
gcuucgcuac uuggagccac uauugacuac gcaucaugg 360

<210> 4

<211> 363

<212> DNA

<213> Artificial Sequence

<220>

WO 00/44895

PCT/DE00/00244

3

<223> Description of the artificial sequence:
DNA which corresponds to a sequence from the
positive control DNA of the HeLa Nuclear
Extract in vitro transcription kit from
Promega

<400> 4

```

tcggacccctc agaagctta atgcggtagt ttatcacagt taaaatgtca acggcagtcag 60
gcacccgtgta taaaatctaa caatgcgtcc atcgatccatcc tggcaccgtt caccctggat 120
gtgttaggca taggtttggt tatgcggta ctggccggcc ttttgcggga tategtccat 180
tccgacacca tgcgcagtcg ttagggcggtt ctgtctgcgc tatatgcgtt gatgcatttt 240
ctatgegecac ccgttctcgg agactgtcc gacccgttttgc gcccggcccc agtctctgttc 300
gtttcgttac ttggacccac tategtactac gegatcatgg cgaccacacc cgtctctgtgg 360
atc

```

<210> 5

<211> 315

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:

Sequence from the YFP gene

<400> 5

auggugagca agggggaggga gcuguuucacc gggggggggc ccaucttgggu cgaggcuggac 60
 ggggacguaa acggccacaa guucaggcug uccggcgagg ggggggggga ugccaccuac 120
 ggccaaagcuga cccuagaattt caucugccaccc acggggaaacg ugccccggcug cuggccacc 180
 cucugugacca cccugaccua cggcgugcag ugccuucagcc gtuaccccccga ccacalugaag 240
 cggcggacacu uuuucaagguc cggccauugccc gtagggcuacg uccaggagcg ccccaucuuc 300
 uucaaggaaacg acggc 315

<210> 6

<211> 52

52123 DNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:

WO 00/44895

PCT/DE00/00244

4

EcoRI cleavage site, T7 RNA Polymerase promoter, complementary region to the YFP gene

<400> 6

ggaattctaa tacgactcac tataggcgcga atggtgagca agggcgagga gc 52

<210> 7

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:

BamHI cleavage site, SP6 RNA Polymerase promoter, complementary region to the YFP gene

<400> 7

gggatccatt taggtgacac tatagatatac gccgtcgatcc ttgaagaaga tgg 53

<210> 8

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of the artificial sequence:

RNA which corresponds to a sequence from the YFP gene

<400> 8

ucgagcugga cggcgacqua 21

-20-

International Patent Application No. PCT/DE00/00244
of Dr Roland Kreutzer and Dr Stefan Limmer

New Patent Claims

5

1. Method for inhibiting the expression of a given target gene in a cell in vitro, where an oligoribonucleotide with double-stranded structure (dsRNA) formed by two separate RNA single strands is introduced into the cell, where one strand of the dsRNA has a region which is complementary to the target gene, characterized in that the complementary region has less than 25 successive nucleotide pairs.

10

2. Method according to claim 1, where the dsRNA is enclosed by micellar structures, preferably by liposomes.

15

3. Method according to either of the preceding claims, where the dsRNA is enclosed by natural viral capsids or by chemically or enzymatically produced artificial capsids or structures derived therefrom.

20

4. Method according to one of the preceding claims, where the target gene is expressed in eukaryotic cells.

25

5. Method according to one of the preceding claims, where the target gene is selected from the following group: oncogene, cytokin gene, Id-protein gene, development gene, prion gene.

30

6. Method according to one of the preceding claims, where the target gene is expressed in pathogenic organisms, preferably in plasmodia.

AMENDED SHEET

7. Method according to one of the preceding claims, where the target gene is part of a virus or viroid.

5

8. Method according to claim 7, where the virus is a virus or viroid which is pathogenic for humans.

9. Method according to claim 7, where the virus or 10 viroid is a virus or viroid which is pathogenic for animals or phytopathogenic.

10. Method according to one of the preceding claims, where segments of the dsRNA are in double-stranded 15 form.

11. Method according to one of the preceding claims, where the ends of the dsRNA are modified in order 20 to counteract degradation in the cell or dissociation into the single strands.

12. Method according to one of the preceding claims, where the cohesion of the double-stranded structure, which is caused by the complementary 25 nucleotide pairs, is increased by at least one, preferably two, further chemical linkage(s).

13. Method according to one of the preceding claims, where the chemical linkage is formed by a covalent 30 or ionic bond, a hydrogen bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal-ion coordination.

14. Method according to one of the preceding claims, 35 where the chemical linkage is generated at at least one, preferably both, ends of the double-stranded structure.

- 12 -

15. Method according to one of the preceding claims, where the chemical linkage is formed by means of one or more compound groups, the compound groups preferably being poly(oxyphosphinicooxy-1,3-propanediol) and/or polyethylene glycol chains.
5
16. Method according to one of the preceding claims, where the chemical linkage is formed by purine analogs used in the double-stranded structure in place of purines.
10
17. Method according to one of the preceding claims, where the chemical linkage is formed by azabenzeno units introduced into the double-stranded structure.
15
18. Method according to one of the preceding claims, where the chemical linkage is formed by branched nucleotide analogs used in the double-stranded structure in place of nucleotides.
20
19. Method according to one of the preceding claims, where at least one of the following groups is used for generating the chemical linkage: methylene blue; bifunctional groups, preferably bis(2-chloroethyl)amine; N-acetyl-N'-(p-glyoxylbenzoyl)cystamine; 4-thiouracil; psoralene.
25
- 30 20. Method according to one of the preceding claims, where the chemical linkage is formed by thiophosphoryl groups provided at the ends of the double-stranded structure.
- 35 21. Method according to one of the preceding claims, where the chemical linkage at the ends of the double-stranded structure is formed by triple-helix bonds.

- 23 -

22. Method according to one of the preceding claims,
where at least one 2'-hydroxyl group of the
nucleotides of the dsRNA in the double-stranded
5 structure is replaced by a chemical group,
preferably a 2'-amino or a 2'-methyl group.

23. Method according to one of the preceding claims,
where at least one nucleotide in at least one
10 strand of the double-stranded structure is a
locked nucleotide with a sugar ring which is
chemically modified, preferably by a 2'-O, 4'-C-
methylene bridge.

15 24. Method according to one of the preceding claims,
where the dsRNA is bound to, associated with or
surrounded by, at least one viral coat protein
which originates from a virus, is derived
therefrom or has been prepared synthetically.

20 25. Method according to one of the preceding claims,
where the coat protein is derived from
polyomavirus.

25 26. Method according to one of the preceding claims,
where the coat protein contains the polyomavirus
virus protein 1 (VP1) and/or virus protein 2
(VP2).

30 27. Method according to one of the preceding claims,
where, when a capsid or capsid-type structure is
formed from the coat protein, one side faces the
interior of the capsid or capsid-type structure.

35 28. Method according to one of the preceding claims,
where one strand of the dsRNA is complementary to
the primary or processed RNA transcript of the
target gene.

-24-

29. Method according to one of the preceding claims, where the cell is a vertebrate cell or a human cell.

5

30. Method according to one of the preceding claims, where at least two dsRNAs which differ from each other are introduced into the cell, where at least segments of one strand of each dsRNA are complementary to in each case one of at least two different target genes.

10

31. Method according to one of the preceding claims, where one of the target genes is the PKR gene.

15

32. Medicament with at least one oligoribonucleotide with double-stranded structure (dsRNA) formed by two separate RNA single strands for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region which is complementary to the target gene, characterized in that the complementary region has less than 25 successive nucleotide pairs.

20

33. Medicament according to claim 32, where the dsRNA is enclosed by micellar structures, preferably by liposomes.

25

30 34. Medicament according to either of claims 32 or 33, where the dsRNA is enclosed by natural viral capsids or by chemically or enzymatically produced artificial capsids or structures derived therefrom.

35

35. Medicament according to one of claims 32 to 34, where the target gene can be expressed in eukaryotic cells.

- 25 -

36. Medicament according to one of claims 32 to 35, where the target gene is selected from the following group: oncogene, cytokin gene, Id-protein gene, development gene, prion gene.
5
37. Medicament according to one of claims 32 to 36, where the target gene can be expressed in pathogenic organisms, preferably in plasmodia.
10
38. Medicament according to one of claims 32 to 37, where the target gene is part of a virus or viroid.
15
39. Medicament according to claim 38, where the virus is a virus or viroid which is pathogenic for humans.
20
40. Medicament according to claim 38, where the virus or viroid is a virus or viroid which is pathogenic for animals.
25
41. Medicament according to one of claims 32 to 40, where segments of the dsRNA are in double-stranded form.
30
42. Medicament according to one of claims 32 to 40, where the ends of the dsRNA are modified in order to counteract degradation in the cell or dissociation into the single strands.
35
43. Medicament according to one of claims 32 to 42, where the cohesion of the double-stranded structure, which is caused by the complementary nucleotide pairs, is increased by at least one, preferably two, further chemical linkage(s).
35

- 26 -

44. Medicament according to one of claims 32 to 43,
where the chemical linkage is formed by a covalent
or ionic bond, a hydrogen bond, hydrophobic
interactions, preferably van-der-Waals or stacking
interactions, or by metal-ion coordination.

5

45. Medicament according to one of claims 32 to 44,
where the chemical linkage is generated at at
least one, preferably both, ends of the double-
stranded structure.

10

46. Medicament according to one of claims 32 to 45,
where the chemical linkage is formed by means of
one or more compound groups, the compound groups
15 preferably being poly(oxyphosphinicooxy-
1,3-propanediol) and/or polyethylene glycol
chains.

47. Medicament according to one of claims 32 to 46,
20 where the chemical linkage is formed by purine
analogs used in the double-stranded structure in
place of purines.

48. Medicament according to one of claims 32 to 47,
25 where the chemical linkage is formed by azabenzene
units inserted into the double-stranded structure.

49. Medicament according to one of claims 32 to 48,
30 where the chemical linkage is formed by branched
nucleotide analogs used in the double-stranded
structure in place of nucleotides.

50. Medicament according to one of claims 32 to 49,
35 where at least one of the following groups is used
for generating the chemical linkage: methylene
blue; bifunctional groups, preferably bis(2-
chloroethyl)amine; N-acetyl-N'-(p-glyoxylbenzoyl)-
cystamine; 4-thiouracil; psoralene.

- 27 -

51. Medicament according to one of claims 32 to 50, where the chemical linkage is formed by thiophosphoryl groups provided at the ends of the double-stranded structure.
- 5 52. Medicament according to one of claims 32 to 51, where the chemical linkage are [sic] triple-helix bonds provided at the ends of the double-stranded structure.
- 10 53. Medicament according to one of claims 32 to 52, where at least one 2'-hydroxyl group of the nucleotides of the dsRNA in the double-stranded structure is replaced by a chemical group, preferably a 2'-amino or a 2'-methyl group.
- 15 54. Medicament according to one of claims 32 to 53, where at least one nucleotide in at least one strand of the double-stranded structure is a locked nucleotide with a sugar ring which is chemically modified, preferably by a 2'-O, 4'-C-methylene bridge.
- 20 55. Medicament according to one of claims 32 to 54, where the dsRNA is bound to, associated with or surrounded by, at least one viral coat protein which originates from a virus, is derived therefrom or has been prepared synthetically.
- 25 56. Medicament according to one of claims 32 to 55, where the coat protein is derived from the polyomavirus.
- 30 57. Medicament according to one of claims 32 to 56, where the coat protein contains the polyomavirus virus protein 1 (VP1) and/or virus protein 2 (VP2).

- 28 -

58. Medicament according to one of claims 32 to 57, where, when a capsid or capsid-type structure is formed from the coat protein, one side faces the interior of the capsid or capsid-type structure.
- 5 59. Medicament according to one of claims 32 to 58, where one strand of the dsRNA is complementary to the primary or processed RNA transcript of the target gene.
- 10 60. Medicament according to one of claims 32 to 59, where the cell is a vertebrate cell or a human cell.
- 15 61. Medicament according to one of claims 32 to 60, where at least two dsRNAs which differ from each other are contained in the medicament, where at least segments of one strand of each dsRNA are complementary to in each case one of at least two different target genes.
- 20 62. Medicament according to claim 61, where one of the target genes is the PKR gene.
- 25 63. Active ingredient with at least one oligoribonucleotide with double-stranded structure (dsRNA) formed by two separate RNA single strands for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region which is complementary to the target gene, and where the target gene is part of a phytopathogenic virus or viroid, characterized in that the complementary region has less than 35 successive nucleotide pairs.
- 30
- 35

- 29 -

64. Active ingredient according to claim 63, where the target gene can be expressed in eukaryotic cells.
- 5 65. Active ingredient according to claim 63 or 64, where segments of the dsRNA are in double-stranded form.
- 10 66. Active ingredient according to one of claims 63 to 65, where the ends of the dsRNA are modified in order to counteract degradation in the cell or dissociation into the single strands.
- 15 67. Active ingredient according to one of claims 63 to 66, where the cohesion of the double-stranded structure, which is caused by the complementary nucleotide pairs, is increased by at least one, preferably two, further chemical linkage(s).
- 20 68. Active ingredient according to one of claims 63 to 67, where the chemical linkage is formed by a covalent or ionic bond, a hydrogen bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal-ion coordination.
- 25 69. Active ingredient according to one of claims 63 to 68, where the chemical linkage is generated at at least one, preferably both, ends of the double-stranded structure.
- 30 70. Active ingredient according to one of claims 63 to 69, where the chemical linkage is formed by means of one or more compound groups, the compound groups preferably being poly(oxyphosphinicooxy-1,3-propanediol) and/or polyethylene glycol chains.

- 30 -

71. Active ingredient according to one of claims 63 to 70, where the chemical linkage is formed by purine analogs used in the double-stranded structure in place of purines.

5

72. Active ingredient according to one of claims 63 to 71, where the chemical linkage is formed by azabenzene units inserted into the double-stranded structure.

10

73. Active ingredient according to one of claims 63 to 72, where the chemical linkage is formed by branched nucleotide analogs used in the double-stranded structure in place of nucleotides.

15

74. Active ingredient according to one of claims 63 to 73, where at least one of the following groups is used for generating the chemical linkage: methylene blue; bifunctional groups, preferably bis(2-chloroethyl)amine; N-acetyl-N'-(p-glyoxyl-benzoyl)cystamine; 4-thiouracil; psoralene.

20

75. Active ingredient according to one of claims 63 to 74, where the chemical linkage is formed by thiophosphoryl groups provided at the ends of the double-stranded structure.

25

76. Active ingredient according to one of claims 63 to 75, where the chemical linkage are triple-helix bonds provided at the ends of the double-stranded structure.

30

77. Active ingredient according to one of claims 63 to 76, where at least one 2'-hydroxyl group of the nucleotides of the dsRNA in the double-stranded structure is replaced by a chemical group, preferably a 2'-amino or a 2'-methyl group.

- 31 -

78. Active ingredient according to one of claims 63 to 77, where at least one nucleotides at least one strand of the double-stranded structure is a locked nucleotide with a sugar ring which is chemically modified, preferably by a 2'-O, 4'-C-methylene bridge.

5

79. Active ingredient according to one of claims 63 to 78, where one strand of the dsRNA is complementary to the primary or processed RNA transcript of the target gene.

10

80. Active ingredient according to one of claims 63 to 79, where at least two dsRNAs which differ from each other are contained in the active ingredient, where at least segments of one strand of each dsRNA are complementary to in each case one of at 15 least two different target genes.

20 81. Use of an oligoribonucleotide with double-stranded structure (dsRNA) formed by two separate RNA single strands or preparing a medicament or active ingredient for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region which is complementary to the target gene,

25 characterized in that the complementary region has less than 25 successive nucleotide pairs.

30 82. Use according to claim 81, where the dsRNA is enclosed by micellar structures, preferably by liposomes.

35 83. Use according to either of claims 81 or 82, where the dsRNA is enclosed by natural viral capsids or by chemically or enzymatically produced artificial capsids or structures derived therefrom.

AMENDED SHEET

- 32 -

84. Use according to one of claims 81 to 83, where the target gene can be expressed in eukaryotic cells.
- 5 85. Use according to one of claims 81 to 84, where the target gene is selected from the following group: oncogene, cytokin gene, Id-protein gene, development gene, prion gene.
- 10 86. Use according to one of claims 81 to 85, where the target gene can be expressed in pathogenic organisms, preferably in plasmodia.
- 15 87. Use according to one of claims 81 to 86, where the target gene is part of a virus or viroid.
88. Use according to claim 87, where the virus is a virus or viroid which is pathogenic for humans.
- 20 89. Use according to claim 87, where the virus or viroid is a virus or viroid which is pathogenic for animals or phytopathogenic.
90. Use according to one of claims 81 to 89, where segments of the dsRNA are in double-stranded form.
- 25 91. Use according to one of claims 81 to 90, where the ends of the dsRNA are modified in order to counteract degradation in the cell or dissociation into the single strands.
- 30 92. Use according to one of claims 81 to 91, where the cohesion of the double-stranded structure, which is caused by the complementary nucleotide pairs, is increased by at least one, preferably two, further chemical linkage(s).

- 33 -

93. Use according to one of claims 81 to 92, where the chemical linkage is formed by a covalent or ionic bond, a hydrogen bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal-ion coordination.

5

94. Use according to one of claims 81 to 93, where the chemical linkage is generated at at least one, preferably both, ends of the double-stranded structure.

10

95. Use according to one of claims 81 to 94, where the chemical linkage is formed by means of one or more compound groups, the compound groups preferably being poly(oxyphosphinicooxy-1,3-propanediol) and/or polyethylene glycol chains.

15

96. Use according to one of claims 81 to 95, where the chemical linkage is formed by purine analogs used in the double-stranded structure in place of purines.

20

97. Use according to one of claims 81 to 96, where the chemical linkage is formed by azabenzene units introduced into the double-stranded structure.

25

98. Use according to one of claims 81 to 97, where the chemical linkage is formed by branched nucleotide analogs used in the double-stranded structure in place of nucleotides.

30

99. Use according to one of claims 81 to 98, where at least one of the following groups is used for generating the chemical linkage: methylene blue; bifunctional groups, preferably bis(2-chloroethyl)amine; N-acetyl-N'-(p-glyoxylbenzoyl)-cystamine; 4-thiouracil; psoralene.

35

- 34 -

100. Use according to one of claims 81 to 99, where the chemical linkage is formed by thiophosphoryl groups attached to the ends of the double-stranded structure.

5

101. Use according to one of claims 81 to 100, where the chemical linkage at the ends of the double-stranded structure is formed by triple-helix bonds.

10

102. Use according to one of claims 81 to 101, where at least one 2'-hydroxyl group of the nucleotides of the dsRNA in the double-stranded structure is replaced by a chemical group, preferably a 2'-amino or a 2'-methyl group.

20

103. Use according to one of claims 81 to 102, where at least one nucleotide in at least one strand of the double-stranded structure is a locked nucleotide with a sugar ring which is chemically modified, preferably by a 2'-O, 4'-C-methylene bridge.

25

104. Use according to one of claims 81 to 103, where the dsRNA is bound to, associated with or surrounded by, at least one viral coat protein which originates from a virus, is derived therefrom or has been prepared synthetically.

30

105. Use according to one of claims 81 to 104, where the coat protein is derived from polyomavirus.

106. Use according to one of claims 81 to 105, where the coat protein contains the polyomavirus virus protein 1 (VP1) and/or virus protein 2 (VP2).

35

107. Use according to one of claims 81 to 106, where, when a capsid or capsid-type structure is formed

- 35 -

from the coat protein, one side faces the interior of the capsid or capsid-type structure.

108. Use according to one of claims 81 to 107, where
5 one strand of the dsRNA is complementary to the primary or processed RNA transcript of the target gene.

109. Use according to one of claims 81 to 108, where
10 the cell is a vertebrate cell or a human cell.

110. Use according to one of claims 81 to 109, where at least two dsRNAs which differ from each other are used, where at least segments of one strand of
15 each dsRNA are complementary to in each case one of at least two different target genes.

111. Use according to claim 110, where one of the target genes is the PKR gene.
20

112. Use according to one of claims 81 to 111, where the medicament is injectable into the bloodstream or into the interstitium of the organism to undergo therapy.
25

113. Use according to one of claims 81 to 112, where the dsRNA is taken up into bacteria or microorganisms.

30 114. Use of a vector for coding at least one oligoribonucleotide with double-stranded structure (dsRNA) formed by two separate RNA single strands for preparing a medicament or active ingredient for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region
35 which is complementary to the target gene, characterized in that

- 36 -

the complementary region has less than 25 successive nucleotide pairs.

115. Use according to claim 114, where the target gene
5 can be expressed in eukaryotic cells.
116. Use according to claim 114 or 115, where the target gene is selected from the following group:
10 oncogene, cytokin gene, Id-protein gene, development gene, prion gene.
117. Use according to one of claims 114 to 116, where the target gene can be expressed in pathogenic organisms, preferably in plasmodia.
118. Use according to one of claims 114 to 117, where
15 the target gene is part of a virus or viroid.
119. Use according to claim 118, where the virus is a
20 virus or viroid which is pathogenic for humans.
120. Use according to claim 118, where the virus or
25 viroid is a virus or viroid which is pathogenic for animals or phytopathogenic.
121. Use according to one of claims 114 to 120, where
30 segments of the dsRNA are in double-stranded form.
122. Use according to one of claims 114 to 121, where
35 one strand of the dsRNA is complementary to the primary or processed RNA transcript of the target gene.
123. Use according to one of claims 114 to 122, where
the cell is a vertebrate cell or a human cell.
124. Use according to one of claims 114 to 123, where
at least two dsRNAs which differ from each other

- 37 -

are used, where at least segments of one strand of each dsRNA are complementary to in each case one of at least two different target genes.

5 125. Use according to claim 125, where one of the target genes is the PKR gene.

Fetherstonhaugh & Co.
Ottawa, Canada
Patent Agents

1/5




Fig. 1

CA 02359180 2001-07-18

WO 00/44895

PCT/DE00/00244

2/5



Fig. 2

CA 02359180 2001-07-18

WO 00/44895

PCT/DE00/00244

3/5

1 2 3 4 5 6 7 8 9 10 11 12




Fig. 3

4/5


Fig. 4 a



Fig. 4 b



Fig. 4 c



WO 00/44895

PCT/DE00/00244

5/5

Fig. 4 d





Fig. 4 e



SEQUENZPROTOKOLL

<110> Kreutzer Dr., Roland
Limmer Dr., Stephan

5

<120> Verfahren und Medikament zur Hemmung der Expression
eines vorgegebenen Gens

10 <130> 400968

<140>
<141>

15 <150> 199 03 713.2
<151> 1999-01-30

<150> 199 56 568.6
<151> 1999-11-24

20 <160> 8

<170> PatentIn Ver. 2.1

25 <210> 1
<211> 45
<212> DNA
<213> Künstliche Sequenz

30 <220>
<223> Beschreibung der künstlichen Sequenz:
EcoRI-Schnittstelle, T7-RNA-Polymerasepromotor

35 <400> 1
ggaattctaa tacgactcac tatagggcga tcagatctt agaag 45
<210> 2
<211> 50
<212> DNA
40 <213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz:
BamHI-Schnittstelle, SP6-RNA-Polymerasepromotor

5 <400> 2

gggatccatt tagtgacac tatagaatac ccatgatcg 50

<210> 3

10 <211> 340

<212> RNA

<213> Künstliche Sequenz

<220>

15 <223> Beschreibung der künstlichen Sequenz: RNA, die
einer Sequenz aus der "positive control DNA" des
HeLaScribe Nuclear Extract in vitro
Transkriptionskits der Firma Promega entspricht

20 <400> 3

ucagaucu agaagcunua augcggagu uuaucacagu uaaaugcua acgcagucag 60
gcaccgugua ugaaaucuua caauggcgcuc aucgucaucc uggcaccgu caccuggau 120
gcuguaggca uaggcuuggu uaugccggua cugccggcc ucuugcggga uaucguccau 180
uccgacagca ucggcaguca cuauggcugug cugcuagcgc uauaugcguu gaugcaauuu 240
25 cuauggcgac ccguucucgg agcacugucc gaccgcuug gccgcggccc aguccugcuc 300
gcuucgcuac uuggagccac uaucgacuac gcaucaugg 340

<210> 4

30 <211> 363

<212> DNA

<213> Künstliche Sequenz

<220>

35 <223> Beschreibung der künstlichen Sequenz: DNA, die
einer Sequenz aus der "positive control DNA" des
HeLaScribe Nuclear Extract in vitro
Transkriptionskits der Firma Promega entspricht

40 <400> 4

tcagatctct agaagcttta atgcggtagt ttatcacagt taaattgcta acgcagtcag 60

gcaccgtgta tgaaatctaa caatgcgc tcgtcatcc tcggcaccgt caccctggat 120
gctgttaggca taggcttgggt tatgcggta ctgcggggcc tcttgcggga tatcgccat 180
tccgacagca tcgcagtc ctatggcgtg ctgctagcgc tatatgcgtt gatgcaattt 240
ctatgcgcac ccgttctcg agcactgtcc gaccgctttg gccgcgcacc agtcctgctc 300
5 gcttcgtctac ttggagccac tatcgactac gcatcatgg cgaccacacc cgtccctgtgg 360
atc 363

<210> 5
10 <211> 315.
<212> RNA
<213> Künstliche Sequenz

<220>
15 <223> Beschreibung der künstlichen Sequenz: Sequenz aus
dem YFP-Gen

<400> 5
20 auggugagca agggcgagga gcuguucacc gggguggugc ccauccuggu cgagcuggac 60
ggcgacguaa acggccacaa guucagcug uccggcgagg gcgaggcgca ugccaccuac 120
ggcaagcuga cccugaaguu caucugcacc accggcaagc ugcccugcc cuggccacc 180
cucgugacca cccugaccua cggegugcag ugcuucagcc gcuaccccgaa ccacaugaag 240
cagcacgacu ucuucaaguc cgccaugccc gaaggcuacg uccaggagcg caccacuuc 300
uucaaggacg acggc 315
25

<210> 6
30 <211> 52
<212> DNA
<213> Künstliche Sequenz

<220>
<223> Beschreibung der künstlichen Sequenz:
EcoRI-Schnittstelle, T7-RNA-Polymerasepromotor,
35 komplementärer Bereich zum YFP-Gen

<400> 6
ggaattctaa tacgactcac tatagggcga atggtgagca agggcgagga gc 52
40
<210> 7

<211> 53
<212> DNA
<213> Künstliche Sequenz

5 <220>
<223> Beschreibung der künstlichen Sequenz:
BamHI-Schnittstelle, SP6-RNA-Polymerasepromotor,
komplementärer Bereich zum YFP-Gen

10 <400> 7
gggatccatt taggtgacac tatagaatac gccgtcgcc ttgaagaaga tgg 53

<210> 8
15 <211> 21
<212> RNA
<213> Künstliche Sequenz

<220>
20 <223> Beschreibung der künstlichen Sequenz: RNA, die
einer Sequenz aus dem YFP-Gen entspricht

<400> 8
ucgagcugga cggcgacqua a 21
25

INTERNATIONAL SEARCH REPORT

Int'l	Joint Application No
PCT/DE 00/00244	

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/11 A61K31/713

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 19732 A (GENSET) 12 November 1992 (1992-11-12)	1-29, 32-34, 37-43, 45-66, 69-71, 74-80, 82-102, 105-108, 112
Y	abstract, page 11 lines 18-28 pages 12-13, page 15 line 22 bis page 20 line 1, pages 33 and 46, figures 1-6	1-35, 37-43, 45-72, 74-80, 82-108, 110-112
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

6 June 2000

Date of mailing of the international search report

20/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5518 Patentdaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Gore, V

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/DE 00/00244

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 05770 A (ROTHBARTH KARSTEN ; JOSWIG GABY (DE); WERNER DIETER (DE); SCHUBERT) 12 February 1998 (1998-02-12)	1-29, 32-34, 37-43, 45-66, 69-71, 74-80, 82-102, 105-108, 112
Y	abstract, pages 2-3	1-35, 37-43, 45-72, 74-80, 82-108, 110-112
X, P	WO 99 32619 A (CARNEGIE INST OF WASHINGTON ; MONTGOMERY MARY K (US); FIRE ANDREW () 1 July 1999 (1999-07-01)	1-29, 32-34, 37-43, 45-66, 69-71, 74-80, 82-102, 105-108, 112
Y	abstract, pages 6, 11-12, 15-17	15-28, 52-65, 88-101
A	UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE" CHEMICAL REVIEWS, US, AMERICAN CHEMICAL SOCIETY, EASTON, vol. 90, no. 4, 1 June 1990 (1990-06-01), pages 543-584, XP000141412 ISSN: 0009-2665 pages 558, 565-566, 574-575	1-112
	MADHUR K. ET AL.: "Antisense RNA : function and fate of duplex RNA in cells of higher eukaryotes." MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, vol. 62, December 1998 (1998-12), pages 1415-1434, XP000909741 * pages 1422-1423 and 1428 *	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intc	Jonal Application No
PCT/DE 00/00244	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9219732	A 12-11-1992	FR	2675803 A	30-10-1992
		AU	660679 B	06-07-1995
		AU	1759692 A	21-12-1992
		CA	2102229 A	26-10-1992
		EP	0581848 A	09-02-1994
		JP	6506834 T	04-08-1994
WO 9805770	A 12-02-1998	DE	19631919 A	12-02-1998
		EP	0918853 A	02-06-1999
WO 9932619	A 01-07-1999	AU	1938099 A	12-07-1999

INTERNATIONALER RECHERCHENBERICHT

Int. Jonales Aktenzeichen
PCT/DE 00/00244

A. KLASIFIZIERUNG DES ANMELDUNGSGEGENSTANDES
IPK 7 C12N15/11 A61K31/713

Nach der internationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK

B. RECHERCHIERTE GEBIETE

Recherchierte Mindestprüfstoff (Klassifikationssystem und Klassifikationssymbole)
IPK 7 A61K

Recherchierte aber nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Gebiete fallen

Während der internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank und evtl. verwendete Suchbegriffe)

C. ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
X	WO 92 19732 A (GENSET) 12. November 1992 (1992-11-12)	1-29, 32-34, 37-43, 45-66, 69-71, 74-80, 82-102, 105-108, 112
Y	* Zusammenfassung, Seite 11 Z.18-28, Seiten 12-13, Seite 15 Z.22 bis Seite 20 Z.1, Seiten 33 und 46, Abbildungen 1-6 *	1-35, 37-43, 45-72, 74-80, 82-108, 110-112
	—/—	

Weitere Veröffentlichungen sind der Fortsetzung von Feld C zu entnehmen

Siehe Anhang Patentfamilie

* Besondere Kategorien von angegebenen Veröffentlichungen :

"A" Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist

"E" älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist

"L" Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch das Veröffentlichungstermindatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt)

"C" Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benützung, eine Ausstellung oder andere Maßnahmen bezieht

"P" Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist

"T" Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzipieller oder der ltv zugrundeliegenden Theorie angegeben ist

"X" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann allein aufgrund dieser Veröffentlichung nicht als neu oder auf erfindenderischer Tätigkeit beruhend betrachtet werden

"Y" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als auf erfindenderischer Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist

"&" Veröffentlichung, die Mitglied derselben Patentfamilie ist

Datum des Abschlusses der internationalen Recherche

Absendedatum des internationalen Recherchenberichts

6. Juni 2000

20/06/2000

Name und Postanschrift der internationalen Recherchenbehörde
Europäisches Patentamt, P.B. 5818 Patentan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Bevollmächtigter Bediensteter

Gore, V

INTERNATIONALER RECHERCHENBERICHT

Int. Jonaes Aktienzeichen
PCT/DE 00/00244

C.(Fortsetzung) ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
X	WO 98 05770 A (ROTHBARTH KARSTEN ; JOSWIG GABY (DE); WERNER DIETER (DE); SCHUBERT) 12. Februar 1998 (1998-02-12)	1-29, 32-34, 37-43, 45-66, 69-71, 74-80, 82-102, 105-108, 112
Y	* Zusammenfassung, Seiten 2-3 *	1-35, 37-43, 45-72, 74-80, 82-108, 110-112
X, P	WO 99 32619 A (CARNEGIE INST OF WASHINGTON ; MONTGOMERY MARY K (US); FIRE ANDREW ()) 1. Juli 1999 (1999-07-01)	1-29, 32-34, 37-43, 45-66, 69-71, 74-80, 82-102, 105-108, 112
Y	* Zusammenfassung, Seiten 6,11-12,15-17 *	15-28, 52-65, 88-101
	UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE" CHEMICAL REVIEWS, US, AMERICAN CHEMICAL SOCIETY, EASTON, Bd. 90, Nr. 4, 1. Juni 1990 (1990-06-01), Seiten 543-584, XP000141412 ISSN: 0009-2665 * Seiten 558, 565-566, 574-575 *	
A	MADHUR K. ET AL.: "Antisense RNA : - function and fate of duplex RNA in cells of higher eukaryotes." MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, Bd. 62, Dezember 1998 (1998-12), Seiten 1415-1434, XP000909741 Seiten 1422-1423 und 1428	1-112

INTERNATIONALER RECHERCHENBERICHT

Angaben zu Veröffentlichungen, die zur selben Patentfamilie gehören

Internationales Aktenzeichen
PCT/DE 00/00244

Im Recherchenbericht angeführtes Patentdokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie		Datum der Veröffentlichung
WO 9219732 A	12-11-1992	FR	2675803 A	30-10-1992
		AU	660679 B	06-07-1995
		AU	1759692 A	21-12-1992
		CA	2102229 A	26-10-1992
		EP	0581848 A	09-02-1994
		JP	6506834 T	04-08-1994
WO 9805770 A	12-02-1998	DE	19631919 A	12-02-1998
		EP	0918853 A	02-06-1999
WO 9932619 A	01-07-1999	AU	1938099 A	12-07-1999



Office de la Propriété
Intellectuelle
du Canada
Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office
An agency of
Industry Canada

CA 2359180 A1 2000/08/03

(21) 2 359 180

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2000/01/29
(87) Date publication PCT/PCT Publication Date: 2000/08/03
(85) Entrée phase nationale/National Entry: 2001/07/18
(86) N° demande PCT/PCT Application No.: DE 00/00244
(87) N° publication PCT/PCT Publication No.: WO 00/44895
(30) Priorités/Priorities: 1999/01/30 (199 03 713.2) DE;
1999/11/24 (199 56 568.6) DE

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 15/11, A61K 31/713

(71) Demandeurs/Applicants:
KREUTZER, ROLAND, DE;
LIMMER, STEPHAN, DE

(72) Inventeurs/Inventors:
KREUTZER, ROLAND, DE;
LIMMER, STEPHAN, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : METHODE ET MEDICAMENT DESTINES A INHIBER L'EXPRESSION D'UN GENE DONNE
(54) Title: METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE

(57) Abrégé/Abstract:

The invention relates to a medicament containing at least one double-stranded oligoribonucleotide (dsRNA) designed to inhibit the expression of a target gene. According to the invention, one strand of the dsRNA is at least in part complementary to the target gene.

Canada

<http://opic.gc.ca> · Ottawa-Hull K1A 0C9 · <http://cipo.gc.ca>

OPIC · CIPO 191

OPIC CIPO